Title An H 5 N 1 M 2 e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H 1 N 1 virus

Background: A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic

[1]  Shibo Jiang,et al.  Research and development of universal influenza vaccines. , 2010, Microbes and infection.

[2]  Ron A M Fouchier,et al.  Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans , 2009, Science.

[3]  W. Fiers,et al.  Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments , 2009, Expert review of vaccines.

[4]  H. Yoshida,et al.  Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. , 2008, Antiviral research.

[5]  G. Boivin,et al.  Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. , 2008, Vaccine.

[6]  N. Sardesai,et al.  Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens , 2008, PloS one.

[7]  W. Fiers,et al.  An Influenza A Vaccine Based on Tetrameric Ectodomain of Matrix Protein 2* , 2008, Journal of Biological Chemistry.

[8]  W. Fiers,et al.  CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. , 2008, Vaccine.

[9]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[10]  K. Schwarz,et al.  Efficient induction of mucosal and systemic immune responses by virus‐like particles administered intranasally: implications for vaccine design , 2008, European journal of immunology.

[11]  Ying-hua Chen,et al.  Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. , 2005, Microbes and infection.

[12]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[13]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[14]  L. Otvos,et al.  Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. , 2003, Vaccine.

[15]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[16]  J. Tam,et al.  Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. , 1991, Science.

[17]  J. Tam,et al.  Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Antigenic and genetic characteristics of influenza A(H5N1) viruses and candidate vaccine viruses developed for potential use in human vaccines. , 2009, Releve epidemiologique hebdomadaire.